NASDAQ:IKT Inhibikase Therapeutics (IKT) Stock Price, News & Analysis $2.34 -0.07 (-2.74%) As of 10:13 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Inhibikase Therapeutics Stock (NASDAQ:IKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IKT alerts:Sign Up Key Stats Today's Range$2.34▼$2.3950-Day Range$1.96▼$2.5252-Week Range$1.33▼$2.61Volume26,052 shsAverage Volume1.15 million shsMarket Capitalization$327.08 millionP/E RatioN/ADividend YieldN/APrice Target$5.40Consensus RatingBuy Company Overview Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. Read More Inhibikase Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreIKT MarketRank™: Inhibikase Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 723rd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingInhibikase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInhibikase Therapeutics has a consensus price target of $5.40, representing about 124.1% upside from its current price of $2.41.Amount of Analyst CoverageInhibikase Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Inhibikase Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Inhibikase Therapeutics are expected to decrease in the coming year, from ($0.44) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibikase Therapeutics is -5.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibikase Therapeutics is -5.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibikase Therapeutics has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.17% of the float of Inhibikase Therapeutics has been sold short.Short Interest Ratio / Days to CoverInhibikase Therapeutics has a short interest ratio ("days to cover") of 35.53, which indicates bearish sentiment.Change versus previous monthShort interest in Inhibikase Therapeutics has recently increased by 2.78%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibikase Therapeutics does not currently pay a dividend.Dividend GrowthInhibikase Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentInhibikase Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.Search InterestOnly 1 people have searched for IKT on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows2 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.10% of the stock of Inhibikase Therapeutics is held by insiders.Percentage Held by Institutions3.81% of the stock of Inhibikase Therapeutics is held by institutions.Read more about Inhibikase Therapeutics' insider trading history. Receive IKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IKT Stock News HeadlinesInhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Recommendation of "Buy" from BrokeragesSeptember 3, 2026 | americanbankingnews.comInhibikase Therapeutics (NASDAQ:IKT) Shares Down 4.1% - What's Next?September 1, 2026 | americanbankingnews.comDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.September 10 at 1:00 AM | Priority Gold (Ad)Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent ActivityAugust 11, 2026 | globenewswire.comInhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAHJuly 23, 2026 | globenewswire.comInhibikase sells $50M of common stock to RA CapitalJuly 14, 2026 | msn.comInhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) FacilityJuly 14, 2026 | globenewswire.comInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comSee More Headlines IKT Stock Analysis - Frequently Asked Questions How have IKT shares performed this year? Inhibikase Therapeutics' stock was trading at $2.05 at the beginning of 2026. Since then, IKT stock has increased by 17.6% and is now trading at $2.41. How were Inhibikase Therapeutics' earnings last quarter? Inhibikase Therapeutics, Inc. (NASDAQ:IKT) released its earnings results on Tuesday, August, 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. When did Inhibikase Therapeutics' stock split? Inhibikase Therapeutics's stock reverse split on Friday, June 30th 2023.The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Inhibikase Therapeutics IPO? Inhibikase Therapeutics (IKT) raised $20 million in an initial public offering on Wednesday, December 23rd 2020. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. Who are Inhibikase Therapeutics' major shareholders? Inhibikase Therapeutics' top institutional investors include Seven Fleet Capital Management LP (0.25%), Bank of New York Mellon Corp (0.23%), Spark Investment Management LLC (0.01%) and Squarepoint Ops LLC (0.01%). View institutional ownership trends. How do I buy shares of Inhibikase Therapeutics? Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibikase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD) and Intel (INTC). Company Calendar Last Earnings8/11/2026Today9/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IKT's financial health is in the Green zone, according to TradeSmith. IKT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:IKT Previous SymbolNYSE:IKT CIK1750149 Webinhibikase.com Phone(678) 392-3419FaxN/AEmployees6Year Founded2008Price Target and Rating Average Price Target for Inhibikase Therapeutics$5.40 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+128.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-42.80% Return on Assets-40.58% Debt Debt-to-Equity RatioN/A Current Ratio15.82 Quick Ratio15.82 Sales & Book Value Annual Sales$260 thousand Price / Sales1,266.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book1.03Miscellaneous Outstanding Shares139,540,000Free Float129,629,000Market Cap$329.31 million OptionableN/A Beta0.95 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:IKT) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredWashington Is Broke—Could YOUR Savings Be Next?The Department of Justice recently argued in court that cash is not legally property, raising new questions fo...Priority Gold | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredThe $8,000 Gold Call Every Retirement Saver Needs to Read Right NowGold didn't creep higher—it broke $5,000, a level many analysts thought would hold. Now JPMorgan, the biggest ...Golden Crest Metals | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
